Regulatory Application for RG-101 to be Filed in the Near Term: Clinical Studies in Man Expected to Commence in Early 2014
LA JOLLA, Calif., Nov. 4, 2013 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that data demonstrating the positive preclinical profile of RG-101 will be presented in a late-breaking poster session at the 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held in Washington, D.C. on Monday, November 4, 2013 from8:00 a.m. Eastern Standard Time (EST) to 5:30 p.m. EST. The poster is available on the Company’s website at http://www.regulusrx.com.
“RG-101 utilizes a unique mechanism of action by targeting microRNA-122, a liver-specific host factor for stability, replication and translation of HCV. We believe that therapies that target host-encoded factors essential for HCV replication may act as attractive combination agents because they may demonstrate activity across [click to continue…]
COLUMBUS, Ohio, and NEW YORK, Sept. 26, 2013 /PRNewswire/ – The Ohio State University today announced the signing of an exclusive world-wide agreement with Microlin Bio Inc., licensing a large portfolio of Ohio State’s groundbreaking cancer discoveries. The portfolio includes nearly 100 issued and pending microRNA patents that could lead to entirely new, more effective and more targeted ways to diagnose and treat prostate, ovarian, colon and lung cancers. Additionally, Microlin Bio Inc. has licensed a novel nucleic acid delivery technology to deliver these transformational therapies to cancer cells.
These technologies, years in the making, were developed by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) researcher Carlo Croce, M.D., The Ohio State University College of Pharmacy researcher Robert Lee, Ph.D., and collaborators from the National Cancer Institute with the National Institutes of Health.
Just over 10 years ago, Croce was the first in the world to link small cellular molecules called microRNA to cancer. MicroRNAs are now known to play a pivotal role in the growth and spread of many [click to continue…]
Incoming search terms for this article:
Servier selects third cardiovascular target triggering the first milestone under the collaboration
SURESNES, France, and BOULDER, Colo., May 23, 2013 – Servier, a privately-run French research-based pharmaceutical company and a major player in Europe and emerging markets having expertise in the development of treatments for cardiovascular diseases, and miRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA-based therapeutics, announced today that Servier has elected to add a new target as part of its existing agreement for advancing the research, development and commercialization of microRNA-based drug candidates for the treatment of cardiovascular disease. With this selection, Servier and miRagen now have three microRNA programs under development.
“Our selection of a third target is indicative of the strength of our partnership with miRagen, as well as our shared commitment to develop microRNA-based therapies for the treatment of cardiovascular disease,” said Dr. Jean-Paul Vilaine, Head of Servier’s Cardiovascular Research Unit. “We look forward to our continued collaboration to advance promising drug candidates.”
For Dr. Jean-Philippe Seta, Chief Executive Officer of Servier, “Micro-RNA is now the gateway to acting at the deepest level of gene expression regulation, with exciting [click to continue…]